Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1991-7-15
|
| pubmed:abstractText |
Thirteen previously untreated patients with metastatic melanoma entered into a phase II chemo-immunotherapy trial were monitored immunologically during treatment. Treatment consisted of dacarbazine (DTIC) 750 mg/m2 and cisplatin 100 mg/m2 on day 1 followed by interleukin-2 (IL-2) 4 x 10(6) U/m2 by daily intravenous bolus on days 12-16 and 19-23. Cycles were repeated every 28 days. On days 1 (pretreatment), 12, 16, and 23 of each cycle, lymphokine-activated killer (LAK) cell and natural killer cell activity as well as total lymphocyte count and CD3, CD4, CD8, and CD56 lymphocyte subsets were analyzed. Despite pretreatment with full-dose cytotoxic chemotherapy, all patients were able to respond immunologically to IL-2. Spontaneous LAK cell activity was generated by the end of each course of IL-2 administration and persisted for at least 5 days thereafter. Lymphocytosis was maximum at 5 days after IL-2 administration and included increased numbers of all measured lymphocyte subsets. IL-2 administration caused a relative increase in CD56+ cells and a relative decrease in CD3+ cells. There was a direct correlation between the increase in LAK cell activity and the increase in CD56+ lymphocytes. Antitumor responses occurred in five patients but these responses did not correlate with any of the measured changes in LAK activity or lymphocyte subsets. DTIC and cisplatin administered in this schedule does not abrogate the immunological effects of IL-2.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1053-8550
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
147-51
|
| pubmed:dateRevised |
2008-3-18
|
| pubmed:meshHeading |
pubmed-meshheading:2043595-Adolescent,
pubmed-meshheading:2043595-Adult,
pubmed-meshheading:2043595-Aged,
pubmed-meshheading:2043595-Cisplatin,
pubmed-meshheading:2043595-Combined Modality Therapy,
pubmed-meshheading:2043595-Dacarbazine,
pubmed-meshheading:2043595-Drug Evaluation,
pubmed-meshheading:2043595-Female,
pubmed-meshheading:2043595-Humans,
pubmed-meshheading:2043595-Immunophenotyping,
pubmed-meshheading:2043595-Immunotherapy,
pubmed-meshheading:2043595-Interleukin-2,
pubmed-meshheading:2043595-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:2043595-Killer Cells, Natural,
pubmed-meshheading:2043595-Leukocyte Count,
pubmed-meshheading:2043595-Lymphocytes,
pubmed-meshheading:2043595-Male,
pubmed-meshheading:2043595-Melanoma,
pubmed-meshheading:2043595-Middle Aged
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy.
|
| pubmed:affiliation |
Department of Internal Medicine, Wayne State University School of Medicine, Harper Hospital, Detroit, Michigan 48201.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|